FDA 483 and Warning Letter Response and Consulting

What is an FDA Form 483?

An FDA Form 483 lists conditions or practices that an FDA investigator observed during an inspection and believes may violate the Federal Food, Drug, and Cosmetic Act or related requirements. The investigator presents it to company management at the end of the inspection.

A Form 483 is not a final FDA determination that a violation occurred, and it is not necessarily a complete list of every objectionable condition. FDA evaluates the observations together with the Establishment Inspection Report, supporting evidence, the company’s response and its broader compliance history.

How is a Form 483 different from a Warning Letter?

A Form 483 records an investigator’s inspectional observations. A Warning Letter is an agency compliance communication describing significant violations and requesting prompt correction. A Warning Letter can follow unresolved or serious inspection findings, but FDA decides the appropriate action from the complete record.

Both require careful attention. Consequences can include follow-up inspection, product or submission delays, import action, seizure, injunction or other enforcement depending on the facts. A Form 483 should not be described as a Warning Letter or final adjudication.

Is a Form 483 response required within 15 business days?

FDA does not state that a written response to every Form 483 is legally required. However, FDA policy generally considers a response received within 15 business days before deciding whether to issue a Warning Letter. A response received later may still be evaluated, but it may arrive after the agency has acted.

Companies should begin immediately, confirm the deadline and submission instructions with the FDA contact, and avoid making commitments they cannot support. The response should address every observation, distinguish completed corrections from planned corrective actions and provide objective evidence.

How should a company respond to FDA inspection observations?

A defensible response normally includes:

• A point-by-point acknowledgement of each observation
• Immediate containment or correction where needed to protect patients or product
• A documented root-cause investigation
• Corrective and preventive actions tied to the root cause
• Owners, realistic completion dates and interim controls
• Evidence already available and a schedule for later evidence
• Effectiveness checks showing that the actions solved the systemic problem

The response should align with the company’s quality management system. Overly broad promises, unsupported completion claims and attachments that are not mapped to an observation can weaken the submission. Long-running remediation should be followed by organized status updates.

What happens after the response is submitted?

FDA can review the response, request more information, classify the inspection, conduct a follow-up inspection or take compliance action. There is no universal time to close a Form 483 or Warning Letter. Resolution depends on the seriousness and scope of the findings, the quality of the evidence and whether FDA verifies effective correction.

Form 483 records and related inspection materials may become publicly available through FDA disclosure processes, subject to applicable redactions. Companies should write each response as an accurate regulatory record while still protecting legitimately confidential information.